May 14 |
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
|
May 2 |
NeuroSense Announces First Quarter 2024 Business Update
|
Apr 22 |
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
|
Apr 18 |
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
|
Apr 12 |
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
|
Apr 10 |
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
|
Apr 9 |
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
|
Feb 21 |
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
|
Jan 30 |
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
|
Jan 9 |
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
|